Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Keeping Track: Another Gene Therapy Approval, Several Priority Review Designations, And Many Resubmissions

Executive Summary

The latest drug development news and highlights from our US FDA Performance Tracker.

Advertisement

Related Content

Kite's Gene Therapy Yescarta Gets Biosimilar Treatment With Second-In-Class Approval
Gilead/Kite Pricing For Yescarta Undercuts Novartis's CAR-T Kymriah
Keeping Track: US FDA Approvals Of Mavyret, Idhifa, Vyxeos Headline Week Of Breakthroughs, Hematology And Hematology BTDs
AstraZeneca Hopes Imfinzi Breakthrough Get Can Burn Off MYSTIC Failure
Novartis CAR-T Site Selection, Risk Management Are Model For Other Sponsors
Keeping Track: Oncology Filings Galore In Run-Up To ASCO Meeting
AstraZeneca's Imfinzi Steals March Into Untapped IO Lung Cancer Territory
Keeping Track: US FDA Approves Emflaza And Parsabiv, Turns Down Opioid/Anti-Emetic Combo CL-108
Pacira’s Exparel Problems: CR Letter Stops New Indication
Pacira's long-acting non-opioidpain drug gets FDA ok

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS121811

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel